{"product_id":"targets-and-emerging-therapies-for-schizophrenia-9780470322826","title":"Targets and Emerging Therapies for Schizophrenia","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e* Covering a wide range of receptors and molecular targets, this book provides a comprehensive resource for neuro-drug discovery and molecular targets for schizophrenia.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003e\u003cp\u003e“In summary, this book provides a timely and convenient reflection on schizophrenia drug discovery and development, which has been a major component of psychiatric drug research for several decades.”  (\u003ci\u003eChemMedChem\u003c\/i\u003e, 1 March 2013)\u003c\/p\u003e \u003cp\u003e \u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003ePreface vii\u003c\/p\u003e \u003cp\u003eContributors xi\u003c\/p\u003e \u003cp\u003eIntroduction 1\u003cbr\u003e \u003ci\u003eAlan J. Cross\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1 Dopaminergic Hypothesis of Schizophrenia: A Historical Perspective 5\u003cbr\u003e \u003ci\u003eAurelija Jucaite and Svante Nyberg\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2 Dopamine D2\/D3 Partial Agonists as Antipsychotics 37\u003cbr\u003e \u003ci\u003ePhilip G. Strange\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3 D1\/D5 Dopamine Agonists as Pharmacotherapy for Schizophrenia 51\u003cbr\u003e \u003ci\u003eKevin N. Boyd and Richard B. Mailman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4 Phosphodiesterase Inhibitors as a Novel Therapeutic Approach for Schizophrenia 85\u003cbr\u003e \u003ci\u003eJudith A. Siuciak and William J. Pitts\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5 Glutamatergic Synaptic Dysregulation in Schizophrenia 115\u003cbr\u003e \u003ci\u003eJoseph T. Coyle, Alo Basu, and Michael Benneyworth\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6 Metabotropic Glutamate 2\/3 Receptor Agonists and Positive Allosteric Modulators of Metabotropic Glutamate Receptor 2 as Novel Agents for the Treatment of Schizophrenia 143\u003cbr\u003e \u003ci\u003eGerard J. Marek, Bruce J. Kinon, David L. McKinzie, Jeffrey M. Schkeryantz, and James A. Monn\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7 AMPA Receptor Positive Modulators 187\u003cbr\u003e \u003ci\u003eJohn A. Morrow, John K.F. Maclean, and Craig Jamieson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8 Progress in the Exploration and Development of GlyT1 Inhibitors for Schizophrenia 233\u003cbr\u003e \u003ci\u003eJeffrey S. Albert and Michael W. Wood\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9 Combined Dopamine D2 and 5-Hydroxytryptamine (5-HT)1A Receptor Strategies for the Treatment of Schizophrenia: A Pharmacological and Chemical Perspective 255\u003cbr\u003e \u003ci\u003eAndrew C. McCreary, Roelof W. Feenstra, and Caitlin A. Jones\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10 5-HT2C and 5-HT6 Receptor Targeted Emerging Approaches in Schizophrenia 273\u003cbr\u003e \u003ci\u003eSharon Rosenzweig-Lipson, John Dunlop, Lee E. Schechter, Thomas A. Comery, Jonathan Gross, and Karen L. Marquis\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11 The Cholinergic Hypothesis: An Introduction to the Hypothesis and a Short History 295\u003cbr\u003e \u003ci\u003eJoseph I. Friedman, Isabella Kanellopoulou, and Vladan Novakovic\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12 α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia 319\u003cbr\u003e \u003ci\u003eMihály Hajós and Bruce N. Rogers\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13 Muscarinic Acetylcholine Receptors as Novel Targets for the Development of Therapeutics for Schizophrenia 355\u003cbr\u003e \u003ci\u003eChristian C. Felder, David L. McKinzie, Richard C. Thompson, and Bin Liu\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14 Will Modulation of Neuropeptide Receptors Produce the Next Generation of Antipsychotic Drugs? A Focus on the Neurokinin and Neurotensin Systems 381\u003cbr\u003e \u003ci\u003eLee A. Dawson, Paul W. Smith, and Jeannette M. Watson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15 GABA and Schizophrenia 425\u003cbr\u003e \u003ci\u003eJohn H. Kehne and George D. Maynard\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIndex 469\u003c\/p\u003e","brand":"John Wiley \u0026 Sons Inc","offers":[{"title":"Default Title","offer_id":49402315178327,"sku":"9780470322826","price":151.16,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780470322826.jpg?v=1730480043","url":"https:\/\/bookcurl.com\/products\/targets-and-emerging-therapies-for-schizophrenia-9780470322826","provider":"Book Curl","version":"1.0","type":"link"}